Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02548169 · ClinicalTrials.gov registry record · Phase 1
Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer
A Phase 1 study, sponsored by Baylor Research Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT02548169: Clinical Trial Phase 1 study, sponsored by Baylor Research Institute.
NCT02548169 is a Phase 1 study that was terminated before completion, run by Baylor Research Institute. The registered enrollment target is 7 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02548169, a Phase 1 study, was terminated before completion, sponsored by Baylor Research Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary objective is to confirm clinical safety and feasibility of combining the antigen-loaded Dendritic Cell (DC) vaccine with chemotherapy including folinic acid, oxaliplatin, irinotecan and 5-Fluorouracil (5FU) (FOLFIRINOX) and nab-paclitaxel/gemcitabine in patients with pancreatic cancer. The secondary objectives of this trial are to determine preliminary clinical efficacy based on response rates, overall survival and progression free survival compared with historic control, and surgical conversion rate as defined as percent of locally advanced (unresectable) patients achieving resectability within 6 months of treatment initiation. Also, to identify vaccine immunogenicity by measuring acquired, T cell-mediated immune activating events post-vaccination and to correlate clinical response with acquired immune responses.
Primary Outcome
Follow up for toxicity will be recorded for the first 30 days following the last DC vaccination and any long-term toxicity will be followed for 3 years after completing study therapy.
Interventions
- BIOLOGICAL DC Vaccine + Standard of Care Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-04-24 |
| Phase | Phase 1 |
Why NCT02548169 stopped before completion
NCT02548169 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 1 intervention - of which DC Vaccine + Standard of Care Chemotherapy is the first listed.
NCT02548169 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02548169 about?
NCT02548169 is a clinical study titled "Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer". The primary objective is to confirm clinical safety and feasibility of combining the antigen-loaded Dendritic Cell (DC) vaccine with chemotherapy including folinic acid, oxaliplatin, irinotecan and 5-Fluorouracil (5FU) (FOLFIRINOX) and nab-paclitaxel/gemcitabine in patients with pancreatic cancer. ...
What is the current status of trial NCT02548169?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2015-08. Estimated completion is 2017-04-24.
What interventions are being tested in trial NCT02548169?
The interventions under investigation include: DC Vaccine + Standard of Care Chemotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT02548169?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02548169's enrollment target sits among peer trials
7 1972nd of 2000 higher than 27 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia